

## Overview

### Useful For

Preferred test for routine aluminum screening

Monitoring metallic prosthetic implant wear

### Special Instructions

- [Metals Analysis Specimen Collection and Transport](#)

### Method Name

Triple-Quadrupole Inductively Coupled Plasma Mass Spectrometry (ICP-MS/MS)

### NY State Available

Yes

## Specimen

### Specimen Type

Whole blood

### Specimen Required

**\*\*\*This specimen container cannot be opened or used for any other testing before shipping.\*\*\***

**Patient Preparation:** High concentrations of gadolinium and iodine are known to potentially interfere with most inductively coupled plasma mass spectrometry-based metal tests. If either gadolinium- or iodine-containing contrast media has been administered, **a specimen should not be collected for 96 hours.**

#### Supplies:

-Greiner Bio-One VACUETTE TUBE 6 mL NH Trace Elements Sodium Heparin tube (T819)

-Metal Free Specimen Vial (T173)

**Container/Tube:** Greiner Bio-One VACUETTE TUBE 6 mL NH Trace Elements Sodium Heparin tube

**Specimen Volume:** 1 mL

**Collection Instructions:** See [Metals Analysis Specimen Collection and Transport](#) for complete instructions.

### Forms

If not ordering electronically, complete, print, and send a [Renal Diagnostics Test Request](#) (T830) with the specimen.

### Specimen Minimum Volume

0.4 mL

### Reject Due To

Gross hemolysis	OK
Gross lipemia	OK
Gross icterus	OK

## Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Whole blood	Refrigerated	14 days	

## Clinical & Interpretive

### Clinical Information

Under normal physiologic conditions, the usual daily dietary intake of aluminum (5-10 mg) is eliminated completely. Excretion is accomplished by avid filtration of aluminum from the blood by the glomeruli of the kidney. Patients in kidney failure lose the ability to clear aluminum and are at risk for aluminum toxicity.

Many factors increase the incidence of aluminum toxicity in patients with kidney failure:

- Aluminum-laden dialysis water can expose dialysis patients to aluminum.
- Aluminum-laden albumin can expose patients to an aluminum burden they cannot eliminate.
- The dialysis process is not highly effective at eliminating aluminum.
- Aluminum-based phosphate binder gels are administered orally to minimize phosphate accumulation; a small fraction of this aluminum may be absorbed and accumulated.

If it is not removed by kidney filtration, aluminum accumulates in the blood where it binds to proteins such as albumin and is rapidly distributed through the body. Aluminum overload leads to accumulation of aluminum at two sites: brain and bone. Brain deposition has been implicated as a cause of dialysis dementia. In bone, aluminum replaces calcium at the mineralization front, disrupting normal osteoid formation.

Deposition of aluminum in bone also interrupts normal calcium exchange. The calcium in bone becomes unavailable for resorption back into blood under the physiologic control of parathyroid hormone (PTH) and results in secondary hyperparathyroidism.

While PTH is typically quite elevated in kidney failure, two different processes may occur:

- 1) High-turnover bone disease associated with high PTH (>150 pg/mL) and relatively low aluminum (<20 ng/mL)
- 2) Low-turnover bone disease with lower PTH (<50 pg/mL) and high aluminum (>60 ng/mL). Low-turnover bone disease indicates aluminum intoxication.

Blood aluminum concentrations are likely to be increased above the reference range in patients with metallic joint prosthesis. Prosthetic devices produced by Zimmer Company and Johnson and Johnson typically are made of aluminum, vanadium, and titanium. Prosthetic devices produced by Depuy Company, Dow Corning, Howmedica, LCS, PCA, Osteonics, Richards Company, Tricon, and Whiteside, typically are made of chromium, cobalt, and molybdenum. This list of products is incomplete, and these products change occasionally; see the prosthesis product information of each device for composition details.

---

**Reference Values**

0-17 years: Not established

> or =18 years: <5 ng/mL

**Interpretation**

Internal exposure, which can be determined from aluminum levels in blood, is a significantly better measure for assessing aluminum-related neurotoxicity. Early signs of neurotoxicity have been reported in plasma concentrations starting at 13 ng/mL, but any elevation must take into account the full clinical history and other clinical signs and symptoms and test results. Previous studies have reported a whole blood to serum ratio for aluminum of approximately 1.7.(1)

The McCarthy(2) and Hernandez(3) describe a biochemical profile that is characteristic of aluminum overload disease in dialysis patients:

- Patients in kidney failure with no signs or symptoms of osteomalacia or encephalopathy usually had serum aluminum below 20 ng/mL and parathyroid hormone (PTH) concentrations above 150 pg/mL, which is typical of secondary hyperparathyroidism.
- Patients with signs and symptoms of osteomalacia or encephalopathy had serum aluminum above 60 ng/mL and PTH concentrations below 50 pg/mL (PTH above the reference range, but low for secondary hyperparathyroidism).
- Patients who had serum aluminum above 60 ng/mL but below 100 ng/mL were identified as candidates for later onset of aluminum-overload disease and required aggressive efforts to reduce their daily aluminum exposure. This was done by switching them from aluminum-containing phosphate binders to calcium-containing phosphate binders, by ensuring that their dialysis water had less than 10 ng/mL of aluminum, and ensuring the albumin used during postdialysis therapy was aluminum free.

Prosthesis wear is known to result in increased circulating concentration of metal ions.(4) A modest increase (6-10 ng/mL) in serum aluminum concentration is likely to be associated with a prosthetic device in good condition. Serum concentrations above 10 ng/mL in a patient with an aluminum-based implant not undergoing dialysis suggest significant prosthesis wear. Increased serum trace element concentrations in the absence of corroborating clinical information do not independently predict prosthesis wear or failure.

**Cautions**

Failure to pay attention to proper specimen collection procedures can cause abnormal results due to specimen contamination, which can lead to misinterpretation and misdiagnosis:

- Most of the common evacuated blood collection devices have rubber stoppers that are comprised of aluminum-silicate. Simple puncture of the rubber stopper for blood collection is sufficient to contaminate the specimen with aluminum. Typically, blood drawn in standard evacuated blood tubes will be contaminated by 20 to 60 ng/mL aluminum.
- The use of wooden applicator sticks or pipette tips during specimen aliquoting can cause abnormal results due to contamination.

**Clinical Reference**

1. Schultze B, Lind PM, Larsson A, Lind L. Whole blood and serum concentrations of metals in a Swedish population-based sample. *Scand J Clin Lab Invest.* 2014;74(2):143-148. doi:10.3109/00365513.2013.864785
2. McCarthy JT, Milliner DS, Kurtz SB, Johnson WJ, Moyer TP. Interpretation of serum aluminum values in dialysis patients. *Am J Clin Pathol.* 1986;86(5):629-636
3. Hernandez JD, Wesseling K, Salusky IB. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy. *Semin Dial.* 2005;18(4):290-295

4. Liu TK, Liu SH, Chang CH, Yang RS. Concentration of metal elements in the blood and urine in the patients with cementless total knee arthroplasty. *Tohoku J Exp Med.* 1998;185(4):253-262
5. Schwarz C, Sulzbacher I, Oberbauer R. Diagnosis of renal osteodystrophy. *Eur J Clin Invest.* 2006;36 Suppl 2:13-22
6. Sharma AK, Toussaint ND, Pickering J, Beeston T, Smith ER, Holt SG. Assessing the utility of testing aluminum levels in dialysis patients. *Hemodial Int.* 2015;19(2):256-262. doi:10.1111/hdi.12231
7. Riihimaki V, Aitio A. Occupational exposure to aluminum and its biomonitoring in perspective. *Crit Rev Toxicol.* 2012;42(10):827-853. doi:10.3109/10408444.2012.725027
8. Strathmann FG, Blum LM. Toxic elements In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. *Tietz Textbook of Laboratory Medicine.* 7th ed. Elsevier; 2023:455e55
9. US Department of Health and Human Services. Toxicological profile for aluminum. HHS: Agency for Toxic Substances and Disease Registry. 2006. Accessed March 18, 2026. Available at [www.atsdr.cdc.gov/toxprofiles/tp22.pdf](http://www.atsdr.cdc.gov/toxprofiles/tp22.pdf)
10. Willhite CC, Karyakina NA, Yokel RA, et al. Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts. *Crit Rev Toxicol.* 2014;44 Suppl 4(Suppl 4):1-80. doi:10.3109/10408444.2014.934439
11. Kazi TG, Jalbani N, Kazi N, et al. Evaluation of toxic metals in blood and urine samples of chronic renal failure patients, before and after dialysis. *Ren Fail.* 2008;30(7):737-745. doi:10.1080/08860220802212999
12. Chuang PH, Tsai KF, Wang IK, et al. Blood Aluminum Levels in Patients with Hemodialysis and Peritoneal Dialysis. *Int J Environ Res Public Health.* 2022;19(7):3885. doi:10.3390/ijerph19073885
13. Rucker D, Thadhani R, Tonelli M. Trace element status in hemodialysis patients. *Semin Dial.* 2010;23(4):389-395
14. Klotz K, Weistenhofer W, Neff F, Hartwig A, van Thriel C, Drexler H. The Health Effects of Aluminum Exposure. *Dtsch Arztebl Int.* 2017;114(39):653-659. doi:10.3238/arztebl.2017.0653

## Performance

### Method Description

The metal of interest is analyzed by triple-quadrupole inductively coupled plasma mass spectrometry.(Unpublished Mayo method)

### PDF Report

No

### Day(s) Performed

Tuesday through Friday

### Report Available

1 to 5 days

### Specimen Retention Time

14 days

### Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Superior Drive

---

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

82108

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
ALWB	Aluminum, B	5575-6

Result ID	Test Result Name	Result LOINC® Value
622056	Aluminum, B	5575-6